Relatlimab
ATC — · 7 markets · 9 records
Relatlimab
Forms
AU 3 records · 3 strengths
- 80 mg/20 mLinjectionOPDUALAG
- 85.2 mginjectionOPDUALAG nivolumab 240mg and relatlimab 80mg in 20mL concentrate solution for IV infusion vial
Records without a stated strength · 1 OPDUALAG
US 1 records · 1 strengths
- 4 mginjectionOPDUALAG
GB 1 records · 1 strengths
- 80 mg/20 mLinjectionOpdualag 240mg/20ml / 80mg/20ml concentrate for solution for infusion vials
CA 1 records · 1 strengths
- 4 mg/1 mLliquidOPDUALAG
SG 1 records · 1 strengths
Records without a stated strength · 1 OPDUALAG CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/80MG
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 OPDUALAG
The same ingredient can carry completely different
brand names in different countries, and the same name can point to a different ingredient.
Listed by country — not interchangeable.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.
A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.